A Study of Residual Curarization Incidence in China

Summary

The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.

Conditions

• Perioperative/Postoperative Complications
• PORC (Postoperative Residual Curarization)

Interventions

DRUG

Vecuronium Bromide

Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.

DRUG

Rocuronium

Administrative protocol of rocuronium is determined by each caregiver's clinical experience.

DRUG

Cisatracurium

Administrative protocol of cisatracurium is determined by each caregiver's clinical experience

Sponsors & Collaborators

• Ruijin Hospital

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Shanghai Zhongshan Hospital

  collaborator OTHER

• The First Affiliated Hospital of Guangzhou Medical University

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• Eastern Hepatobiliary Surgery Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Zhujiang Hospital

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• First Affiliated Hospital, Sun Yat-Sen University

  collaborator OTHER

• The First Affiliated Hospital of Zhengzhou University

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• Central South University

  collaborator OTHER

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• First Affiliated Hospital of Zhejiang University

  collaborator OTHER

• China Medical University Hospital

  collaborator OTHER

• Hebei Medical University Fourth Hospital

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Peking University First Hospital

  lead OTHER

Principal Investigators

• Xinmin Wu, Doctor · Peking University First Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-10-31

Primary Completion

2014-10-31

Completion

2014-12-31

Countries

• China

Study Locations